Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

571 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study.
Théroux P, Alexander J Jr, Pharand C, Barr E, Snapinn S, Ghannam AF, Sax FL. Théroux P, et al. Among authors: barr e. Circulation. 2000 Nov 14;102(20):2466-72. doi: 10.1161/01.cir.102.20.2466. Circulation. 2000. PMID: 11076818 Clinical Trial.
Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive management. PRISM-PLUS Investigators.
Théroux P, Alexander J Jr, Dupuis J, Pesant Y, Gervais P, Grandmont D, Kouz S, Laramée P, Huynh T, Barr E, Sax FL; PRISM-PLUS Investigators. Théroux P, et al. Among authors: barr e. Am J Cardiol. 2001 Feb 15;87(4):375-80. doi: 10.1016/s0002-9149(00)01386-2. Am J Cardiol. 2001. PMID: 11179517 Clinical Trial.
Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina With Aggrastat [tirofiban]] and Determine Cost of Therapy with Invasive or Conservative Strategy)-TIMI 18 trial.
Weintraub WS, Culler SD, Kosinski A, Becker ER, Mahoney E, Burnette J, Spertus JA, Feeny D, Cohen DJ, Krumholz H, Ellis SG, Demopoulos L, Robertson D, Boccuzzi SJ, Barr E, Cannon CP. Weintraub WS, et al. Among authors: barr e. Am J Cardiol. 1999 Feb 1;83(3):317-22. doi: 10.1016/s0002-9149(98)00860-1. Am J Cardiol. 1999. PMID: 10072215 Clinical Trial.
Quadrivalent human papillomavirus vaccine.
Barr E, Tamms G. Barr E, et al. Clin Infect Dis. 2007 Sep 1;45(5):609-7. doi: 10.1086/520654. Epub 2007 Jul 25. Clin Infect Dis. 2007. PMID: 17682997 Review.
Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines.
Garland SM, Steben M, Hernandez-Avila M, Koutsky LA, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Esser MT, Vuocolo SC, Nelson M, Railkar R, Sattler C, Barr E; 012 Study Investigators. Garland SM, et al. Among authors: barr e. Clin Vaccine Immunol. 2007 Jun;14(6):792-5. doi: 10.1128/CVI.00478-06. Epub 2007 Apr 11. Clin Vaccine Immunol. 2007. PMID: 17428949 Free PMC article. Clinical Trial.
571 results